

1 Longitudinal testing for SARS-CoV-2 RNA in day care centers in Hesse,  
2 Germany, during increased local incidence and with VOC Alpha as  
3 dominant variant: Results of the SAFE KiDS 2 and SAFE KiDS 3 study  
4 Barbara Schenk, Sebastian Hoehl, Olga Rudych, Dominic Menger, Samira Farmand,  
5 Franziska Wrobel, Emilie Kreutzer, Daniela Gebert, Melanie Flohr, Franziska Berger, Vanessa  
6 Weigel, Marhild Kortenbusch, Annemarie Berger, Sandra Ciesek

7 Institute of Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt am  
8 Main, Germany, Paul-Ehrlich-Str. 40, D-60596 Frankfurt am Main, Germany

9

10 Word Count: 2 485, Abstract 220

11 Corresponding author: [sebastian.hoehl@kgu.de](mailto:sebastian.hoehl@kgu.de); Phone: +49 69 6301 83062

12

## 13 Abstract

14 In the summer of 2020, we investigated the rate of inapparent shedding of SARS-CoV-2 in a  
15 representative sample of day care centers from Hesse, Germany, and found a low positivity  
16 rate during a period of low local community spread.

17 To investigate the influence of a high local incidence setting, we conducted the *SAFE KiDS 2*  
18 study. 577 children and 334 staff members of 47 day care centers were tested for respiratory  
19 and gastrointestinal shedding of SARS-CoV-2, and three infections with SARS-CoV-2 in the  
20 infectious period were detected. We conclude that viral shedding occurred infrequently while  
21 the original "wild-type" variant was dominant.

22 The more transmissible SARS-CoV-2 variant Alpha (B.1.1.7) became the dominant strain after  
23 *SAFE KiDS 2* was concluded. The *SAFE KiDS 3* study investigated the impact of the Alpha  
24 variant of SARS-CoV-2 on inapparent viral shedding in the day care setting. In this study, 756  
25 children and 226 staff members from 46 day care centers provided self-collected saliva swabs,  
26 the so-called "Lollipop" swabs, which were tested by RT-PCR. In the four-week study period,  
27 none of the participants tested positive for SARS-CoV-2 RNA, demonstrating that inapparent  
28 shedding of SARS-CoV-2 in the day care setting was also rare during the dominance of the  
29 Alpha variant.

30 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**  
The influence of the variant of concern Delta on day care centers has yet to be studied.

## 31 Introduction

32 In the early pandemic of COVID-19, many countries closed day care centers as measure to  
33 curb community spread of the virus. While children of kindergarten age rarely have severe  
34 disease when infected with SARS-CoV-2 <sup>1-3</sup> measures of public health, such as distancing and  
35 wearing of masks, cannot be applied to the same extend in day care centers as in other  
36 educational facilities. Nevertheless, a growing body of evidence suggested a limited role of  
37 day care centers in community spread of *wild type* SARS-CoV-2 in Central Europe in 2020 and  
38 early 2021<sup>4-8</sup>. However, some of these studies were conducted during low community  
39 activity<sup>4,5</sup>, limiting the transferability to a setting with increased community spread. One of these  
40 studies was the *SAFE KiDS study*, which we conducted in the summer of 2020 in 50 day care  
41 centers in the state of Hesse, Germany<sup>4</sup>. In this 12-week longitudinal study, we neither  
42 detected respiratory nor gastrointestinal shedding of SARS-CoV-2 in any of 825 children  
43 attending day care, and only in two staff members.

44 But the arrival of the more transmissible variant of concern (VOC) Alpha (B.1.1.7) in Germany  
45 in the beginning of 2021<sup>9</sup> had the potential of new transmission dynamics, which may also  
46 influence inapparent viral shedding in day care centers<sup>10,11</sup>. This could also have an impact on  
47 effective hygiene concepts of regular operation "under hygienic conditions".

48 To evaluate potential changes to the epidemiology of SARS-CoV-2 in the day care setting we  
49 investigated the frequency of shedding of SARS CoV-2 in day care centers in Hesse, Germany,  
50 in a second and third round of the *SAFE KiDS study: SAFE KiDS 2 and SAFE KiDS 3*, which  
51 were conducted from January 18<sup>th</sup> to February 11<sup>th</sup>, 2021 at a high incidence setting (local 7-  
52 day incidence: 23.75 to 281.43 cases / 100,000 inhabitants) during the dominance of the  
53 original *wild type* and from May 17<sup>th</sup> to June 11<sup>th</sup>, 2021 with the Alpha variant being the  
54 dominant SARS-CoV-2 variant (local 7-day incidence: 4.73 to 124.61 cases / 100,000  
55 inhabitants) in Germany, respectively. In both studies, children and staff members self-  
56 collected swabs at home that subsequently were tested by real time (RT)-PCR for SARS CoV-  
57 2.

58

## 59 Methods

### 60 Study design

61 The *SAFE KiDS 2* and *SAFE KiDS 3* study in general replicated the study protocol from the  
62 *SAFE KiDS* study <sup>4</sup>, with some alterations.

63 Day care centers that had already participated in the original *SAFE KiDS* study were invited to  
64 participate, and, in case the facility declined to participate, further day care centers were  
65 chosen from a representative sample and invited. For *SAFE KiDS 2* and *SAFE KiDS 3* study,  
66 47 and 46 facilities were recruited, respectively. 30 participants from each facility,  
67 comprising both children and staff members, were invited. Parents were asked to collect  
68 swabs weekly from their children at home before visiting the day care center: both a buccal  
69 mucosa swab as well as an anal swab (“dual swab”) in the *SAFE KiDS 2* study (according to  
70 the original study protocol from the *SAFE KiDS* study) and only a so-called “Lollipop” swab in  
71 the *SAFE KiDS 3* study.

72 To collect the “Lollipop” swab <sup>12</sup>, children were asked to suck a dry swab for 30 seconds under  
73 the supervision of their parents until the swab was saturated with saliva. Staff members  
74 provided the same sort of swabs.

75 Participants received written instructions explaining the goal of the study as well as the  
76 swabbing procedure. Written consent was obtained. Testing of children by the parents was  
77 only to be performed in compliance with the child, and never forced. Providing samples was  
78 voluntary each week for all participants.

### 79 Laboratory testing

80 Testing for SARS-CoV-2 was performed at the Institute of Medical Virology, Goethe University  
81 Frankfurt, Germany. Before proceeding to Real-time (RT)-PCR testing, samples were pooled  
82 in a 10-sample group-testing mini-pool protocol, to preserve reagents while maintain high  
83 diagnostic sensitivity <sup>13</sup>. For this purpose, the swabs were incubated and agitated in 1.8 ml  
84 virus deactivating buffer for approximately three minutes to generate the archive tubes. After  
85 incubation, swabs were squeezed and 10 swabs were pooled into one vial containing 2.7 ml  
86 virus deactivating buffer, agitated and incubated for at least three minutes before being  
87 removed and discarded. The archive tubes were stored at 4°C and the PCR pool was tested  
88 by RT-PCR for SARS-CoV-2 on the Roche cobas® 6800 instrument (Roche diagnostics,  
89 Basel, Switzerland) according to manufacturer instructions. In case of a negative result in the  
90 pooled sample, all individual samples received a negative test result. When at least one of the  
91 two PCR targets (E-gene or ORF-region) was detected, all samples of the pool, the archive  
92 tubes, were individually tested. For all individual samples yielding a positive result for either

93 one or both PCR targets, the public health authority was informed in accordance with the  
94 German Infection Protection Act.

95 All positive samples were also screened for the presence of key mutations of SARS-CoV-2  
96 VOC Alpha (N501Y, del69/70, E484K) by melt curve analysis (VirSNiP SARS-CoV-2 Spike  
97 N501Y, del69/70, E484K assays; TIB Molbiol, Berlin, Germany), or, if this was not possible  
98 due to low viral load, samples were tested with a RT-PCR protocol targeting the S-gene  
99 (TaqPath™ COVID-19 CE-IVD RT-PCR Kit, ThermoFischer Scientific, Waltham, USA) to  
100 determine whether a drop-out of S-gene detectability occurs in the positive samples of this  
101 study, which would be consistent with the presence of the Alpha variant (B.1.1.7) <sup>14</sup>.

## 102 Statistical analysis

103 The studies were analyzed in a descriptive statistical assessment due to the low incidence  
104 rates.

## 105 Ethical approval

106 This study protocol was approved by the ethics board of the University Hospital Frankfurt,  
107 Goethe University Frankfurt am Main, Germany.

## 108 Role of the funding source

109 The *SAFE KiDS 2 and the SAFE KiDS 3* study were commissioned by the Hessian Ministry of  
110 Social Affairs and Integration and were supported by Roche, Basel, Switzerland. The funder  
111 of the study did not contribute to study design, data collection, data analysis, data  
112 interpretation, or writing and submitting of the report for publication.

113

114

## 115 Results

### 116 Results of the SAFE KiDS 2 study

#### 117 Study participants and sample distribution

118 47 day care centers participated in this four-week-study. 577 children (age range 5 months to  
119 6 years of age; age median 4 years) and 334 staff members were enrolled and provided at  
120 least one swab. 5,019 swabs (2,837 buccal mucosa (56.5 %) and 2,182 anal swabs (43.5 %))  
121 were tested in total. 837 swabs (36.6 %) were provided by staff and 3,182 swabs (63.4 %)  
122 were provided by children.

#### 123 Results of testing for SARS-CoV-2 by RT-PCR

124 We detected SARS-CoV-2 in buccal mucosa swabs of two of 577 children. Gastrointestinal  
125 shedding was detected in five additional children, resulting in at least one positive swab in  
126 1.21% of the children (seven out of 577). There was no case with both a positive buccal  
127 mucosa and anal swab (table 1). In one out of 334 staff members gastrointestinal shedding of  
128 SARS-CoV-2 RNA was detected. All other swabs provided by staff members were negative.

#### 129 Description of the detected cases

130 The Ct values of the eight SARS-CoV-2 positive swabs ranged from 31.5 to 36.73 (see table  
131 1). In the first study week of the *SAFE KiDS 2* study, two SARS-CoV-2 infections were detected  
132 in children via the buccal mucosa swab and four SARS-CoV-2 infections were detected in  
133 three additional children and one staff member via anal swab (see table 1). The SARS-CoV-2  
134 cases occurred in five different day care centers, with the first and second cases and the third  
135 and fourth cases detected in study participants of the same day care center. In the second  
136 week of the study, no additional SARS-CoV-2 infections were identified with similar numbers  
137 of participants. One infection was detected in a child via anal swab in each of the third and  
138 fourth study week. All study participants who tested positive had always provided both swab  
139 specimens on the day of PCR testing, which were also tested individually by PCR. In no case  
140 were both swabs positive.

141 The eight results obtained were forwarded to the relevant health authorities. Only in the first  
142 three cases the detected SARS-CoV-2 infection was confirmed by independent testing of a  
143 respiratory swab by the health department. In one case of gastrointestinal viral shedding, a  
144 past infection was known; in three cases a past infection was suspected due to SARS-CoV-2  
145 infections in the household of the study participant prior to the study. In none of the eight cases,  
146 according to the health authorities, were further transmissions detected in the day care center  
147 during the study period (see Table 1). However, the local health authorities determined that in  
148 six of the eight cases other persons in the household were also infected with SARS-CoV-2.  
149 Only in two cases no other SARS-CoV-2 infections were detected in the household.

150 Community activity of SARS-CoV-2 in Hesse during the study

151 Local 7-day incidence rates per 100,000 population ranged from 66.01 to 138.71 in the five  
152 counties of study participants who tested positive for SARS-CoV-2. Overall, 7-day incidence  
153 rates for all participating urban and rural counties ranged from 23.75 to 281.43.

154 Mutation analysis

155 Due to low viral load in all samples with a positive result for SARS-CoV-2, key mutations from  
156 the “variants of concern” Alpha could not be successfully examined using a melt curve analysis.  
157 In an alternative approach, we applied the S-gene-targeted PCR assay to test for a drop-out  
158 of S-gene-detectability characteristic for the Alpha variant. Due to the high Ct values of the  
159 samples, the assay was indeterminable for two samples, for six samples a S-gene drop-out  
160 was not detected (meaning the S-gene was detected) (table 1), suggesting that the Alpha  
161 variant was not present in these samples.

162

## 163 Results of the SAFE KiDS 3 study

### 164 Study participants and sample distribution

165 The *SAFE KiDS 3* study was conducted from May 17<sup>th</sup> to June 11<sup>th</sup>, 2021, when the Alpha  
166 variant was the dominant virus variant in Hesse, Germany<sup>15</sup>. In the four-week study, 756  
167 children (age range 5 months to 7 years of age; age median 4 years) and 226 staff members  
168 of 46 day care centers in Hesse, Germany, participated. In total, 2,964 “Lollipop” swabs were  
169 tested for SARS-CoV-2 RNA by RT-PCR. 626 (21.1 %) swabs were provided by staff members  
170 and 2,338 (78.9 %) swabs were provided by children.

### 171 Community activity of SARS-CoV-2 in Hesse during the study

172 7-day incidence rates for all participating urban and rural counties ranged from 4.73 to 124.61  
173 cases / 100,000 inhabitants.

### 174 Results of testing for SARS-CoV-2 by RT-PCR

175 None of the 2,964 swabs tested positive for SARS-CoV-2 RNA. None of the study participants  
176 reported that SARS-CoV-2 infection was detected outside of the study.

177

178

## 179 Discussion

180 Building on the *SAFE KiDS* study, we examined the rate of inapparent viral shedding of SARS-  
181 CoV-2 in the day care setting during two additional time periods.

182 In the *SAFE KiDS 2* study, conducted with the “dual swabs” method of testing for both  
183 respiratory and gastrointestinal shedding during moderately high local incidence, SARS-CoV-  
184 2 was detected in seven out of 577 children (1.2 %) and in one out of 334 staff members  
185 (0.3%). Only three of these cases had evidence of respiratory viral shedding. Out of these,  
186 SARS-CoV-2 was detected in the buccal mucosa swab collected in the study in two children.  
187 In one case, SARS-CoV-2 was detected in an anal swab with subsequent independent testing  
188 by the local health department.

189 In five cases (four in children and one in staff), only gastrointestinal shedding of SARS-CoV-2  
190 was detected, but not concurrent respiratory shedding. This suggests that residual  
191 gastrointestinal shedding was present after the acute phase of infection. In fact, in one case,  
192 a past infection was known before the beginning of the study; in three other cases, a past  
193 infection from household exposure was suspected. The other cases of gastrointestinal viral  
194 shedding may also be due to past infections that went unnoticed. Therefore, a low rate of  
195 inapparent viral shedding among children attending the day care center can be noted.

196 To determine the presence of the variant Alpha, which was demonstrated to be more  
197 infectious<sup>16,17</sup>, in the *SAFE KiDS 2* study we further analyzed the eight positive samples for an  
198 S-gene drop-out by RT-PCR, which would indicate that the Alpha variant was present. No  
199 S-gene drop-out was detected. Thus, the effects of the Alpha variant on day care centers have  
200 likely not yet influenced the *SAFE KiDS 2* study and were therefore investigated in a third round  
201 of the study.

202 The *SAFE KiDS 3* study was conducted when the Alpha variant was the main circulating  
203 variant in Germany<sup>15</sup>. Since the gastrointestinal detection of SARS-CoV-2 RNA in the *SAFE*  
204 *KiDS 2* study did not provide evidence for an infection during the infectious period, but rather  
205 a past infection in the majority of cases, screening for gastrointestinal shedding was omitted in  
206 the *SAFE KiDS 3* study. Instead, the so-called “Lollipop” swab was applied to test for  
207 respiratory shedding.

208 Although even more children participated in the *SAFE KiDS 3* study compared to *SAFE KiDS*  
209 *2* (756 vs. 577), none of the provided swabs tested positive for SARS-CoV-2 in the RT-PCR  
210 pooling protocol.

211 The evaluation of a questionnaire at the end of both studies did not identify a case where our  
212 protocol with “dual swab” testing or “Lollipop” testing failed to detect an infection.



213 In conclusion, interpreted with other recent studies from central Europe <sup>6,7</sup> the results of the  
214 *SAFE KiDS 2* study suggest a limited role of day care centers in the transmission dynamics of  
215 SARS-CoV-2 even at a high incidence setting. Although the number of infections and  
216 transmissions in young children and day care centers has increased upon the arrival of the  
217 more contagious variant Alpha in Germany <sup>10,11</sup>, we did not identify a SARS-CoV-2 infection in  
218 the 756 participating children during a period at which Alpha was the dominant circulating  
219 variant in the *SAFE KiDS 3* study. The absence of detected SARS-CoV-2 infections in the  
220 *SAFE KiDS 3* study is in line with a decline in the local 7-day incidence at the end of the “third  
221 wave” in Germany. Seasonality may also have contributed to the decline<sup>18</sup>, in addition to the  
222 progressing vaccination campaign. Moreover, a high vaccination quote among the day care  
223 staff, as has been reported by the participants of the study, might contribute to decreasing  
224 infection numbers in day care centers in the pandemic.

225 Our study has limitations. This includes that study duration and material was not consistent in  
226 all three rounds of the study, limiting comparability of results. All samples were collected  
227 without observation by a medical professional, which may have influenced testing sensitivity.  
228 Also, since study participation was on a voluntary basis, biases may have also effected the  
229 results of the study. We only tested for inapparent shedding, but transmissions were not  
230 examined as part of the study.

231 For the upcoming weeks of the pandemic, it can be assumed that the currently dominant virus  
232 variant Alpha will be displaced by the VOC Delta. Whether the even more infectious variant  
233 Delta <sup>19</sup> will influence transmission among children and thus the incidence of infection in day  
234 care centers in the future has to be investigated in further studies.

235

236

237

238

## 239 Figures

240

241 Table 1

No.	Study week	Day care center	Type of shedding	Child or adult	Ct ORF-1 <sup>1)</sup>	Ct E-gene <sup>1)</sup>	Ct S-gene <sup>2)</sup>	Symptoms at time of testing	Confirmation by independent testing of respiratory sample	Associated cases in the day care center	Associated cases in the household	Local-7-day incidence (out of 100,000 inhabitants)
1	1	1	respiratory	child	32.57	33.53	38.38	none	yes	case no. 2	Yes	127.78
2	1	1	gastrointestinal	child	35.92	36.45	id	none	yes	case no. 1	Yes	127.78
3	1	2	respiratory	child	31.5	32.4	32.08	not known	yes	case no. 4	Yes	116.85
4	1	2	gastrointestinal	adult	36.73	-	34.51	fatigue	no	case no. 3	None	116.85
5	1	3	gastrointestinal	child	33.19	34.47	33.34	none	Known past infection	None	Yes (prior to study)	138.71
6	1	4	gastrointestinal	child	33.85	34.33	33.27	none	no	None	Yes (prior to study)	78.47
7	3	5	gastrointestinal	child	34.46	35.05	35.09	none	no	Yes (prior to study)	Yes (prior to study)	66.01
8	4	6	gastrointestinal	child	36.50	-	id	none	no	None	None	67.1

242

243 Characterization of all eight positive SARS-CoV-2 RT-PCR results determined in the *SAFE KiDS 2* study.

244 <sup>1)</sup> Roche Cobas® SARS-CoV-2 on the Cobas® 6800, Roche diagnostics, Basel, Switzerland

245 <sup>2)</sup> TaqPath™ COVID-19 CE-IVD RT-PCR Kit, ThermoFischer Scientific, Waltham, USA

246 id: indeterminable

247

248

249

250

251

252

253 **Conflicts of Interest**

254 S.C. received research grants and a speaker's fees from Roche diagnostics.

255 S.H. received research support from Roche diagnostics.

256 All other authors report no potential conflicts of interest.

257 **Acknowledgment**

258 We thank Jessica Gille, Regine Jeck, Lena Pompe for technical support and Dr. Ivo Foppa,  
259 Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen, for supplying  
260 information on the local incidences throughout Hesse, Germany.

261 We would further like to thank the Health Protection Authority, City of Frankfurt, and the public  
262 health departments of Kreis Bergstraße, Kreis Groß-Gerau and Wetteraukreis for supplying  
263 information on the epidemiological context and results of case tracings.

264

265

266

267

268

269

## 270 References

- 271 1 Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. *N Engl J Med* 2020; **382**:  
272 1663–65. <https://doi.org/10.1056/NEJMc2005073>.
- 273 2 Souza TH de, Nadal JA, Nogueira RJN, Pereira RM, Brandão MB. Clinical manifestations  
274 of children with COVID-19: A systematic review. *Pediatr Pulmonol* 2020; **55**: 1892–99.  
275 <https://doi.org/10.1002/ppul.24885>.
- 276 3 Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2  
277 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. *JAMA*  
278 *Pediatr* 2020; **174**: 882–89. <https://doi.org/10.1001/jamapediatrics.2020.1467>.
- 279 4 Hoehl S, Kreutzer E, Schenk B, et al. Longitudinal testing for respiratory and  
280 gastrointestinal shedding of SARS-CoV-2 in day care centres in Hesse, Germany. *Clin*  
281 *Infect Dis* 2021. <https://doi.org/10.1093/cid/ciaa1912>.
- 282 5 Tönshoff B, Müller B, Elling R, et al. Prevalence of SARS-CoV-2 Infection in Children and  
283 Their Parents in Southwest Germany. *JAMA Pediatr* 2021; **175**: 586–93.  
284 <https://doi.org/10.1001/jamapediatrics.2021.0001>.
- 285 6 van Loon W, Hommes F, Theuring S, et al. Renewed absence of SARS-CoV-2 infections  
286 in the day care context in Berlin, January 2021. *Clin Infect Dis* 2021.  
287 <https://doi.org/10.1093/cid/ciab199>.
- 288 7 Gilliam WS, Malik AA, Shafiq M, et al. COVID-19 Transmission in US Child Care  
289 Programs. *Pediatrics* 2021; **147**. <https://doi.org/10.1542/peds.2020-031971>.
- 290 8 Lachassinne E, Pontual L de, Caseris M, et al. SARS-CoV-2 transmission among children  
291 and staff in daycare centres during a nationwide lockdown in France: a cross-sectional,  
292 multicentre, seroprevalence study. *Lancet Child Adolesc Health* 2021; **5**: 256–64.  
293 [https://doi.org/10.1016/S2352-4642\(21\)00024-9](https://doi.org/10.1016/S2352-4642(21)00024-9).
- 294 9 Robert Koch-Institut (RKI). Bericht zu den Virusvarianten von SARS-CoV-2 in  
295 Deutschland, from 17 March 2021.  
296 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/DESH/Bericht\\_VOC\\_2021-03-17.pdf?\\_\\_blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/Bericht_VOC_2021-03-17.pdf?__blob=publicationFile).
- 297 1-03-17.pdf?\_\_blob=publicationFile.
- 298 10 Loenenbach A, Markus I, Lehfeld A-S, et al. SARS-CoV-2 variant B.1.1.7 susceptibility  
299 and infectiousness of children and adults deduced from investigations of childcare centre  
300 outbreaks, Germany, 2021. *Euro Surveill* 2021; **26**. <https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100433>.
- 301 7917.ES.2021.26.21.2100433.
- 302 11 Robert Koch-Institut (RKI). Corona-KiTa-Studie: Monatsbericht April 2021.  
303 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Projekte\\_RKI/KiTa-](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/KiTa-Studie-Berichte/KiTASTudie_04_2021.pdf?__blob=publicationFile)  
304 [Studie-Berichte/KiTASTudie\\_04\\_2021.pdf?\\_\\_blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/KiTa-Studie-Berichte/KiTASTudie_04_2021.pdf?__blob=publicationFile).
- 305 12 KiKo (Kita Testung Koeln) Konzept. Version 1.0. [https://kita-testung-koeln.de/wp-](https://kita-testung-koeln.de/wp-content/uploads/2021/03/KIKO_Konzept_Version_1.0_15.03.2021.pdf)  
306 [content/uploads/2021/03/KIKO\\_Konzept\\_Version\\_1.0\\_15.03.2021.pdf](https://kita-testung-koeln.de/wp-content/uploads/2021/03/KIKO_Konzept_Version_1.0_15.03.2021.pdf).

- 307 13 Schmidt M, Hoehl S, Berger A, et al. Novel multiple swab method enables high efficiency  
308 in SARS-CoV-2 screenings without loss of sensitivity for screening of a complete  
309 population. *Transfusion* 2020; **60**: 2441–47. <https://doi.org/10.1111/trf.15973>.
- 310 14 Bal A, Destras G, Gaymard A, et al. Two-step strategy for the identification of SARS-CoV-  
311 2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France,  
312 August to December 2020. *Euro Surveill* 2021; **26**: 2100008.  
313 <https://doi.org/10.2807/1560-7917.ES.2021.26.3.2100008>.
- 314 15 Robert Koch-Institut (RKI). Bericht zu den Virusvarianten von SARS-CoV-2 in  
315 Deutschland, from 23 June 2021.  
316 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/DESH/Bericht\\_VOC\\_2021-06-23.pdf?\\_\\_blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/Bericht_VOC_2021-06-23.pdf?__blob=publicationFile).
- 317 16 Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage  
318 B.1.1.7 in England. *Nature* 2021; **593**: 266–69. <https://doi.org/10.1038/s41586-021-03470-x>.
- 319 17 Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-  
320 CoV-2 lineage B.1.1.7 in England. *Science* 2021; **372**.  
321 <https://doi.org/10.1126/science.abg3055>.
- 322 18 Gaven\v s, Monrad JT, Leech G, et al. Seasonal variation in SARS-CoV-2 transmission in  
323 temperate climates. *medRxiv* 2021. <https://doi.org/10.1101/2021.06.10.21258647>.
- 324 19 Hester Allen\*, MSc, Amoolya Vusirikala\*, MFPH, Joe Flannagan, MSc, Katherine A.  
325 Increased household transmission of COVID-19 cases associated with SARS-CoV-2  
326 Variant of Concern B.1.617.2: a national casecontrol study.  
327 <https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+++national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa>.

332

333

334

335

336